Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer | Zendy

YiLong Wu | Zendy; Li Zhang | Zendy; DongWan Kim | Zendy; Xiaoqing Liu | Zendy; Dae Ho Lee | Zendy; James ChihHsin Yang | Zendy; MyungJu Ahn | Zendy; Johan Vansteenkiste | Zendy; WuChou Su | Zendy; Enriqueta Felip | Zendy; Vincent Chia | Zendy; Sabine Glaser | Zendy; Philippe Pultar | Zendy; Sylvia Zhao | Zendy; Bin Peng | Zendy; Mikhail Akimov | Zendy; Daniel S.W. Tan | Zendy

Open Access

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

Author(s) -

YiLong Wu,

Li Zhang,

DongWan Kim,

Xiaoqing Liu,

Dae Ho Lee,

James ChihHsin Yang,

MyungJu Ahn,

Johan Vansteenkiste,

WuChou Su,

Enriqueta Felip,

Vincent Chia,

Sabine Glaser,

Philippe Pultar,

Sylvia Zhao,

Bin Peng,

Mikhail Akimov,

Daniel S.W. Tan

Publication year - 2018

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2018.77.7326

Subject(s) - gefitinib , medicine , rash , epidermal growth factor receptor , phases of clinical research , egfr inhibitors , clinical endpoint , peripheral edema , adverse effect , erlotinib , pharmacology , tyrosine kinase inhibitor , oncology , cancer , toxicity , clinical trial

MET dysregulation occurs in up to 26% of non-small-cell lung cancers (NSCLCs) after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) treatment. Capmatinib (INC280) is a potent and selective MET inhibitor with preclinical activity in combination with gefitinib in EGFR-mutant, MET-amplified/overexpressing models of acquired EGFR-TKI resistance. This phase Ib/II study investigated the safety and efficacy of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated (amplified/overexpressing) NSCLC who experienced disease progression while receiving EGFR-TKI treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research